Osanetant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Osanetant
Osanetant.png
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
ECHA InfoCard 100.233.307
Chemical and physical data
Formula C35H41Cl2N3O2
Molar mass 606.625 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Osanetant (SR-142,801) was a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo, which was being researched for the treatment of schizophrenia, but was discontinued.[1][2] It was the first non-peptide NK3 antagonist developed in the mid-1990s,[3][4] Other potential applications for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.[5][6]

See also[edit]

References[edit]

  1. ^ "osanetant Sanofi-Aventis discontinued, France.". Highbeam. 
  2. ^ Kamali, F (July 2001). "Osanetant Sanofi-Synthélabo". Current opinion in investigational drugs (London, England : 2000). 2 (7): 950–6. PMID 11757797. 
  3. ^ Emonds-Alt, X; Bichon, D; Ducoux, JP; Heaulme, M; Miloux, B; Poncelet, M; Proietto, V; Van Broeck, D; et al. (1995). "SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor". Life Sciences. 56 (1): PL27–32. PMID 7830490. doi:10.1016/0024-3205(94)00413-M. 
  4. ^ Quartara L, Altamura M (August 2006). "Tachykinin receptors antagonists: from research to clinic". Current Drug Targets. 7 (8): 975–92. PMID 16918326. doi:10.2174/138945006778019381. Retrieved 2011-04-14. 
  5. ^ Desouzasilva, M; Mellojr, E; Muller, C; Jocham, G; Maior, R; Huston, J; Tomaz, C; Barros, M (May 2006). "The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys". European Journal of Pharmacology. 536 (3): 269–78. PMID 16603151. doi:10.1016/j.ejphar.2006.03.010. 
  6. ^ Jocham, Gerhard; Lezoch, Katharina; Müller, Christian P.; Kart-Teke, Emriye; Huston, Joseph P.; De Souza Silva, M. AngéLica (September 2006). "Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core". European Journal of Neuroscience. 24 (6): 1721–32. PMID 17004936. doi:10.1111/j.1460-9568.2006.05041.x.